nivolumab,ipilimumab
bms
['hcrn,gu16,260', 'hcrn,gu,16,260', 'nivo', 'ipi/']
analysis of hcrn gu16-260 (nivo monotherapy w/ salvage ipi/nivo in pts w/ pd/sd)
predictors of nivo mono resistance using wes (n=96) and scrna seq (n=17): focal amplification chrom 11q13 (pd:33% vs cr/pr: 0%) % of slamf7+ cd8+ t cells (pd:33% vs cr/pr:2%) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧